Session XVIII: Predicting and Managing Rare Toxicities in GI Cancer Patients
SO-30: Impact of single heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
